Rani Therapeutics (RANI) vs Tenax Therapeutics (TENX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Rani Therapeutics (RANI) has outperformed Tenax Therapeutics (TENX) over the past year, losing 68.6% versus a loss of 84.7%. Over five years, RANI leads with a -98.3% price change compared with -99.9% for TENX. Rani Therapeutics is the larger company by market cap ($59.0 million vs $56.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RANI | TENX |
|---|---|---|
| Share price | $0.5111 | $1.25 |
| Market cap | $59.03M | $56.92M |
| 1-day change | -11.97% | -10.07% |
| YTD return | -62.14% | -89.75% |
| 1-year return | -68.64% | -84.66% |
| 5-year return | -98.34% | -99.94% |
| EPS (TTM) | $-0.06 | $-1.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.63M | $0 |
| Revenue growth (YoY) | +58.85% | — |
| Net income (latest FY) | $-29.67M | $-52.60M |
| Operating margin | -2345.99% | — |
| Net margin | -1817.09% | — |
| 52-week high | $1.69 | $19.40 |
| 52-week low | $0.502 | $1.24 |
| Distance from 52-week high | -69.76% | -93.56% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1308.73% | +904.80% |
| Average volume | 545.67K | 3.15M |
| Shares outstanding | 115.49M | 45.54M |
| Employees | 69 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RANI has outperformed TENX by 16.0 percentage points over the past year.
About Rani Therapeutics
RANI stock →Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Tenax Therapeutics
TENX stock →Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
RANI vs TENX FAQ
Which is bigger, Rani Therapeutics or Tenax Therapeutics?
Rani Therapeutics (RANI) is larger, with a market capitalization of $59.03M compared with $56.92M for Tenax Therapeutics (TENX).
Which stock has performed better over the past year, RANI or TENX?
RANI returned -68.64% over the past 12 months, compared with -84.66% for TENX (price return, excluding dividends). Past performance does not predict future results.
Are Rani Therapeutics and Tenax Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.